indomethacin has been researched along with Embryopathies in 44 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case is reported in which exposure to cocaine and indomethacin was associated with development of fetal anuria, anasarca, and neonatal gastrointestinal hemorrhage." | 7.68 | Cocaine and indomethacin: fetal anuria, neonatal edema, and gastrointestinal bleeding. ( Angel, JL; Carlan, SJ; Harris, M; O'Brien, WF; Stromquist, C, 1991) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 5.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| " D-Penicillamine may be teratogenic thus it should not be commenced during pregnancy and if a patient becomes pregnant whilst receiving the drug, it should be slowly withdrawn or the dosage reduced." | 4.77 | Antirheumatic medication in pregnancy. ( Brooks, PM; Needs, CJ, 1985) |
| "To test the hypothesis that intrauterine inflammation increases prostaglandin production and may be a risk factor for persistent ductus arteriosus after therapy with indomethacin, a nonselective cyclooxygenase inhibitor." | 3.76 | Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. ( Choi, CW; Choi, JH; Kim, BI; Kim, EK; Kim, ES; Kim, HS; Moon, KC; Park, JS, 2010) |
| "A case is reported in which exposure to cocaine and indomethacin was associated with development of fetal anuria, anasarca, and neonatal gastrointestinal hemorrhage." | 3.68 | Cocaine and indomethacin: fetal anuria, neonatal edema, and gastrointestinal bleeding. ( Angel, JL; Carlan, SJ; Harris, M; O'Brien, WF; Stromquist, C, 1991) |
| "Indomethacin was given for the treatment of preterm labor in a twin pregnancy at a dosage of 200 mg/day for 7 days beginning at 34 weeks and 5 days' gestation." | 3.68 | Indomethacin for preterm labor: fetal toxicity in a dizygotic twin gestation. ( Ayres, NA; Hallak, M; Moise, KJ; Reiter, AA, 1991) |
| " During treatment with the basic drugs: gold, D-penicillamine and chloroquine, pregnancy should be avoided." | 3.65 | [Problems of rheumatic therapy in pregnancy (author's transl)]. ( Bischof, P, 1976) |
| "Forty patients with intact membranes in preterm labor at 23 to 34 weeks' gestation were randomized to receive either intravenous ritodrine or oral indomethacin as the first-line tocolytic agent." | 2.67 | Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. ( Besinger, RE; Johnson, TR; Keyes, WG; Niebyl, JR, 1991) |
| "In all six cases, severe hydramnios occurred during pregnancy between the 26th and 28th week after the last menstrual period." | 2.38 | [Antenatal form of Bartter's syndrome]. ( Broyer, M; Burguet, A; Dechaux, M; Deschenes, G; Garabedian, M; Guyot, C; Hubert, P; Loirat, C, 1993) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 1.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Prenatally diagnosed Ebstein's anomaly with tricuspid valve dysplasia (EA/TVD) is a rare and high-risk congenital heart malformation with limited effective treatments." | 1.72 | Treatment of Severe Fetal Ebstein's Anomaly with Prenatal Nonsteroidal Anti-Inflammatory Therapy. ( Kraus, E; Lannaman, K; Powel, JE; Reddy, C, 2022) |
| "The treatment with Indomethacin in the antenatal period can prevent severe nephrocalcinosis." | 1.36 | Antenatal Bartter syndrome: analysis of two cases with placental findings. ( Aksoy, F; Cetin, A; Dane, B; Dane, C; Yayla, M, 2010) |
| "Persistent patent ductus arteriosus was more common in those infants delivered within 48 hours of maternal indomethacin exposure (40% versus 20% (p<0." | 1.30 | Antenatal indomethacin--adverse fetal effects confirmed. ( Baxendale, H; Harding, J; McCowan, L; McLeay, E; O'Donnell, C; Souter, D, 1998) |
| "Trivial tricuspid valve regurgitation was detected at a mean of 26." | 1.29 | Fetal echocardiography during indomethacin treatment. ( Huhta, JC; Respondek, M; Weil, SR, 1995) |
| "Isolated intestinal perforation has been described in premature neonates who were treated with indomethacin for patent ductus arteriosus." | 1.29 | Isolated small bowel perforation following intrauterine treatment with indomethacin. ( Bidiwala, KS; Delpino, ML; Fejgin, MD, 1994) |
| "When indomethacin was given, arterial blood gases in both groups showed a mild increase in carbon dioxide tension and similar placental blood flows (about 30% of baseline) after bypass." | 1.29 | Exclusion of the placenta during fetal cardiac bypass augments systemic flow and provides important information about the mechanism of placental injury. ( Fenton, KN; Hanley, FL; Heinemann, MK, 1993) |
| "I." | 1.28 | [The neonatal form of Bartter's syndrome: current findings in etiology and physiopathology]. ( Proesmans, WC, 1992) |
| "Indomethacin is a potent agent in the treatment of premature labor, but its use has been limited because of concern about its constrictive effects on the fetal ductus arteriosus." | 1.27 | Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. ( Cano, L; Huhta, JC; Kirshon, B; Moise, KJ; Ou, CN; Sharif, DS; Wasserstrum, N, 1988) |
| "Indomethacin has been most effective but not free of significant complications." | 1.26 | Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem. ( Altmiller, DH; Altshuler, G; Krous, HF; Sharpe, GL, 1979) |
| "Indomethacin was present in fetal blood, and maternal plasma prostaglandin levels were suppressed." | 1.26 | Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe. ( Campbell, W; Garriott, J; Levin, DL; Mills, LJ; Parkey, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (22.73) | 18.7374 |
| 1990's | 23 (52.27) | 18.2507 |
| 2000's | 6 (13.64) | 29.6817 |
| 2010's | 3 (6.82) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Powel, JE | 1 |
| Kraus, E | 1 |
| Reddy, C | 1 |
| Lannaman, K | 1 |
| Han, X | 1 |
| Cui, S | 1 |
| Dane, B | 1 |
| Dane, C | 1 |
| Aksoy, F | 1 |
| Cetin, A | 1 |
| Yayla, M | 1 |
| Kim, ES | 1 |
| Kim, EK | 1 |
| Choi, CW | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Choi, JH | 1 |
| Park, JS | 1 |
| Moon, KC | 1 |
| Grigsby, PL | 1 |
| Novy, MJ | 1 |
| Sadowsky, DW | 1 |
| Morgan, TK | 1 |
| Long, M | 1 |
| Acosta, E | 1 |
| Duffy, LB | 1 |
| Waites, KB | 1 |
| Amsalem, H | 1 |
| Valsky, DV | 1 |
| Yagel, S | 1 |
| Celnikier, DH | 1 |
| Anteby, EY | 1 |
| Kajino, H | 1 |
| Taniguchi, T | 1 |
| Fujieda, K | 1 |
| Ushikubi, F | 1 |
| Muramatsu, I | 1 |
| Garza, J | 1 |
| Clayton, N | 1 |
| Kaviani, A | 1 |
| Maher, TJ | 1 |
| Fauza, D | 1 |
| Respondek, M | 1 |
| Weil, SR | 1 |
| Huhta, JC | 3 |
| Fejgin, MD | 1 |
| Delpino, ML | 1 |
| Bidiwala, KS | 1 |
| Sabik, JF | 1 |
| Heinemann, MK | 2 |
| Assad, RS | 1 |
| Hanley, FL | 2 |
| Van den Veyver, IB | 1 |
| Moise, KJ | 6 |
| Eronen, M | 1 |
| Fenton, KN | 1 |
| Deschenes, G | 1 |
| Burguet, A | 1 |
| Guyot, C | 1 |
| Hubert, P | 1 |
| Garabedian, M | 1 |
| Dechaux, M | 1 |
| Loirat, C | 1 |
| Broyer, M | 1 |
| Murray, HG | 1 |
| Stone, PR | 1 |
| Strand, L | 1 |
| Flower, J | 1 |
| Takahashi, Y | 1 |
| Harada, K | 2 |
| Ishida, A | 1 |
| Tanaka, T | 1 |
| Tsuda, A | 1 |
| Takada, G | 1 |
| Archer, N | 1 |
| Rice, MJ | 1 |
| McDonald, RW | 1 |
| Shiota, T | 1 |
| Ishii, M | 1 |
| Reller, MD | 1 |
| Sahn, DJ | 1 |
| Souter, D | 1 |
| Harding, J | 1 |
| McCowan, L | 1 |
| O'Donnell, C | 1 |
| McLeay, E | 1 |
| Baxendale, H | 1 |
| Humphrey, M | 1 |
| King, G | 1 |
| Tong, H | 1 |
| Wood, CE | 1 |
| Narchi, H | 1 |
| Santos, M | 1 |
| Kulaylat, N | 1 |
| Paek, BW | 1 |
| Jennings, RW | 1 |
| Harrison, MR | 1 |
| Filly, RA | 1 |
| Tacy, TA | 1 |
| Farmer, DL | 1 |
| Albanese, CT | 1 |
| Kumar, R | 1 |
| Sharma, YP | 1 |
| Gupta, I | 1 |
| Altshuler, G | 1 |
| Krous, HF | 1 |
| Altmiller, DH | 1 |
| Sharpe, GL | 1 |
| Levin, DL | 1 |
| Mills, LJ | 1 |
| Parkey, M | 1 |
| Garriott, J | 1 |
| Campbell, W | 1 |
| Bischof, P | 1 |
| Bavoux, F | 1 |
| Proesmans, WC | 1 |
| Díaz-Calderon, O | 1 |
| Velazco-Olivares, M | 1 |
| Danglot-Banck, C | 1 |
| Gómez-Gomez, M | 1 |
| Covarrubias-Villegas, R | 1 |
| Carlan, SJ | 1 |
| Stromquist, C | 1 |
| Angel, JL | 1 |
| Harris, M | 1 |
| O'Brien, WF | 1 |
| Hallak, M | 1 |
| Reiter, AA | 1 |
| Ayres, NA | 1 |
| Besinger, RE | 1 |
| Niebyl, JR | 1 |
| Keyes, WG | 1 |
| Johnson, TR | 1 |
| Momma, K | 1 |
| Takao, A | 1 |
| Sharif, DS | 2 |
| Ou, CN | 1 |
| Kirshon, B | 1 |
| Wasserstrum, N | 2 |
| Cano, L | 1 |
| Fisher, DJ | 1 |
| Martin, C | 1 |
| Needs, CJ | 1 |
| Brooks, PM | 1 |
| Persaud, TV | 2 |
| Moore, KL | 1 |
| O'Grady, JP | 1 |
| Caldwell, BV | 1 |
| Auletta, FJ | 1 |
| Speroff, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial[NCT02819570] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Vaginal Indomethacin Versus Oral Nifedipine for Preterm Labor; a Randomized Controlled Trial[NCT04404686] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
5 reviews available for indomethacin and Embryopathies
| Article | Year |
|---|---|
Prostaglandin synthetase inhibitors in pregnancy.
Topics: Animals; Contraindications; Cyclooxygenase Inhibitors; Female; Fetal Diseases; Forecasting; Humans; | 1993 |
Polyhydramnios: problems and treatment.
Topics: Amniocentesis; Female; Fetal Diseases; Humans; Incidence; Indomethacin; Polyhydramnios; Pregnancy; T | 1993 |
[Antenatal form of Bartter's syndrome].
Topics: Aldosterone; Bartter Syndrome; Calcium; Female; Fetal Diseases; Gestational Age; Humans; Indomethaci | 1993 |
[Fetal toxicity of non-steroidal anti-inflammatory agents].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Fetal Diseases; Heart Failure; Humans; Indomethacin | 1992 |
Antirheumatic medication in pregnancy.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antineoplas | 1985 |
2 trials available for indomethacin and Embryopathies
| Article | Year |
|---|---|
The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study.
Topics: Adult; Blood Flow Velocity; Ductus Arteriosus, Patent; Female; Fetal Diseases; Fetus; Gestational Ag | 1993 |
Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor.
Topics: Amniotic Fluid; Diseases in Twins; Female; Fetal Diseases; Humans; Hypertension, Pulmonary; Indometh | 1991 |
37 other studies available for indomethacin and Embryopathies
| Article | Year |
|---|---|
Treatment of Severe Fetal Ebstein's Anomaly with Prenatal Nonsteroidal Anti-Inflammatory Therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ebstein Anomaly; Female; Fetal Diseases; Heart Defects, Con | 2022 |
Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study.
Topics: Bilirubin; Child; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Fetal Diseases; Hum | 2023 |
Antenatal Bartter syndrome: analysis of two cases with placental findings.
Topics: Adult; Amniocentesis; Amniotic Fluid; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Bar | 2010 |
Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; | 2010 |
Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2012 |
Effect of indomethacin on amniotic fluid prostaglandin and aldosterone levels in a fetus with Bartter syndrome.
Topics: Adult; Aldosterone; Amniotic Fluid; Bartter Syndrome; Cesarean Section; Female; Fetal Diseases; Huma | 2003 |
An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo.
Topics: Animals; Cardiovascular Agents; Drug Interactions; Ductus Arteriosus; Female; Fetal Diseases; Heptan | 2004 |
In situ inhibition of uterine activity by indomethacin: possible relevance to preterm labor prevention after fetal surgery.
Topics: Animals; Depression, Chemical; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Femal | 2004 |
Fetal echocardiography during indomethacin treatment.
Topics: Arterial Occlusive Diseases; Blood Flow Velocity; Constriction, Pathologic; Ductus Arteriosus; Echoc | 1995 |
Isolated small bowel perforation following intrauterine treatment with indomethacin.
Topics: Adult; Female; Fetal Diseases; Humans; Ileal Diseases; Indomethacin; Infant, Newborn; Intestinal Per | 1994 |
High-dose steroids prevent placental dysfunction after fetal cardiac bypass.
Topics: Animals; Bicarbonates; Blood Flow Velocity; Carbon Dioxide; Cardiac Output; Cardiopulmonary Bypass; | 1994 |
Exclusion of the placenta during fetal cardiac bypass augments systemic flow and provides important information about the mechanism of placental injury.
Topics: Animals; Blood Gas Analysis; Carbon Dioxide; Cardiac Output; Extracorporeal Circulation; Female; Fet | 1993 |
Fetal pleural effusion following maternal indomethacin therapy.
Topics: Adult; Cesarean Section; Diseases in Twins; Female; Fetal Diseases; Humans; Indomethacin; Pleural Ef | 1993 |
Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use.
Topics: Constriction, Pathologic; Ductus Arteriosus; Echocardiography; Female; Fetal Diseases; Gestational A | 1993 |
Doppler echocardiographic findings of indomethacin-induced occlusion of the fetal ductus arteriosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Cyclooxygenase Inhibitors; Dilatat | 1996 |
Drug induced closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; | 1996 |
Doppler echocardiographic evaluation of ventricular diastolic filling in fetuses with ductal constriction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Constriction, Pathologic; Ductus Arteriosus; Echocardiograp | 1997 |
Antenatal indomethacin--adverse fetal effects confirmed.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Infant | 1998 |
Re: The debate regarding the risks of tocolytic agents.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Kidney | 1998 |
Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs. Adverse Drug Reactions Advisory Committee.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Australia; Diclofe | 1998 |
Indomethacin attenuates the cerebral blood flow response to hypotension in late-gestation fetal sheep.
Topics: Adrenocorticotropic Hormone; Animals; Arginine Vasopressin; Blood Pressure; Cerebrovascular Circulat | 1999 |
Polyhydramnios as a sign of fetal pseudohypoaldosteronism.
Topics: Adult; Amniocentesis; Cesarean Section; Female; Fetal Diseases; Follow-Up Studies; Gestational Age; | 2000 |
Radiofrequency ablation of human fetal sacrococcygeal teratoma.
Topics: Adult; Catheter Ablation; Electrocardiography; Fatal Outcome; Female; Fetal Diseases; Humans; Indome | 2001 |
Tricuspid regurgitation in a pair of twins at birth secondary to antenatal indomethacin.
Topics: Diseases in Twins; Female; Fetal Diseases; Humans; Indomethacin; Polyhydramnios; Pregnancy; Tocolyti | 2001 |
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem.
Topics: Animals; Brain Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arterio | 1979 |
Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe.
Topics: Animals; Blood Pressure; Ductus Arteriosus; Female; Fetal Diseases; Hypertension, Pulmonary; Indomet | 1979 |
[Problems of rheumatic therapy in pregnancy (author's transl)].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Female; Fetal Diseases | 1976 |
[The neonatal form of Bartter's syndrome: current findings in etiology and physiopathology].
Topics: Bartter Syndrome; Calcium; Fetal Diseases; Fluid Therapy; Humans; Indomethacin; Infant; Infant, Newb | 1992 |
[Indomethacin in threatening premature labor. Fetal and neonatal cardiovascular effects].
Topics: Cardiovascular Diseases; Female; Fetal Diseases; Humans; Hypertension, Pulmonary; Indomethacin; Infa | 1992 |
Cocaine and indomethacin: fetal anuria, neonatal edema, and gastrointestinal bleeding.
Topics: Adult; Anuria; Cocaine; Drug Synergism; Female; Fetal Diseases; Gastrointestinal Hemorrhage; Humans; | 1991 |
Indomethacin for preterm labor: fetal toxicity in a dizygotic twin gestation.
Topics: Abnormalities, Drug-Induced; Adult; Diseases in Twins; Drug Monitoring; Ductus Arteriosus; Female; F | 1991 |
Right ventricular concentric hypertrophy and left ventricular dilatation by ductal constriction in fetal rats.
Topics: Animals; Cardiomegaly; Constriction, Pathologic; Dilatation, Pathologic; Ductus Arteriosus; Female; | 1989 |
Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus.
Topics: Adolescent; Adult; Constriction, Pathologic; Dose-Response Relationship, Drug; Ductus Arteriosus; Ec | 1988 |
Detection and quantitation of constriction of the fetal ductus arteriosus by Doppler echocardiography.
Topics: Animals; Constriction, Pathologic; Ductus Arteriosus; Echocardiography; Female; Fetal Diseases; Huma | 1987 |
Inhibitors of prostaglandin synthesis during pregnancy. 1. Embryopathic activity of indomethacin in mice.
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetal Death; Fetal Diseases; Fetus; Gestational Age; I | 1974 |
Inhibitors of prostaglandin synthesis during pregnancy. 2. The effects of indomethacin in pregnant rats.
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetal Death; Fetal Diseases; Fetus; Growth; Indomethac | 1974 |
The effects of an inhibitor of prostaglandin synthesis (indomethacin) on ovulation, pregnancy, and pseudopregnancy in the rabbit.
Topics: Animals; Chorionic Gonadotropin; Coitus; Corpus Luteum; Depression, Chemical; Female; Fetal Diseases | 1972 |